Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK seeks to market orlistat in Europe

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline's marketing application for a 60 mg nonprescription orlistat weight loss product has been accepted for review by the European Agency for the Evaluation of Medicinal Products, the firm announces Oct. 2. GSK seeks a license to market the drug in all 27 EU member countries, though initial launch markets have not been confirmed, the firm notes. Known in the U.S. as alli, the OTC product was approved by FDA in February (1"The Tan Sheet" Feb. 12, 2007, p. 8). On sale in the U.S. since June, alli is the only FDA-approved weight loss product available without a prescription...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS100978

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel